Why Allstate (ALL) is a Top Value Stock for the Long-Term

Allstate reported $67.7 billion in 2025 revenue, and policies in force were 210.9 million as of Dec. 31, 2025, up 3% year over year. Zacks rates ALL #3 (Hold) but gives it A scores for Value and VGM; six analysts raised fiscal 2026 estimates in the prior 60 days, lifting the consensus by $1.76 to $36.21 per share. The article also cites an average earnings surprise of +45.3% and a forward P/E of 7.07.

Analysis

The investment case is a bet that recent underwriting profitability is sustainable, not that a low forward P/E is independently compelling. In P&C, earnings can look optically cheap near the peak of a pricing cycle: easing premium increases, claims inflation, catastrophe severity, or adverse reserve development can quickly shrink the denominator and erase apparent value. Higher investment income is supportive, but also exposes results to reinvestment rates and credit losses; it does not offset underwriting deterioration automatically.

The article is promotional, and its favorable estimate revisions sit alongside a Zacks Hold rating. Neither the cited surprise history nor a value score establishes normalized earnings power. Before underwriting the valuation, verify the latest underlying combined ratio, catastrophe losses, reserve development, renewal pricing versus loss-cost trends, and investment portfolio credit quality. No competitor-specific read-through is established; if Allstate’s pricing discipline weakens, the relevant relative test is whether peers such as Progressive, Travelers, and Chubb preserve underwriting margins better.

Near term, this is not an event-driven catalyst. Over 1–3 months, earnings revisions and the next results can validate or undermine the estimate trajectory. Over 6–18 months, the key question is whether rate adequacy and retention sustain underwriting returns as the cycle evolves. The contrarian risk is that investors may treat cyclical earnings as durable; the upside case is that a genuinely low valuation is being applied to normalized, improving returns.

Key Decisions for Investors

• Do not initiate on the promotional value-score argument alone. Treat ALL as a watchlist candidate until current combined-ratio trends, catastrophe-adjusted results, reserve development, and renewal pricing versus loss costs are verified.
• Conditional trade: consider a measured long ALL versus a diversified P&C peer basket only if reported underwriting performance confirms stable or improving margins and estimates continue to rise. Reassess or exit the relative thesis if ALL’s underlying combined ratio deteriorates, reserve strengthening appears, or guidance/revisions turn down.
• For the next 1–3 months, monitor earnings revisions and reported underwriting metrics rather than the quoted valuation multiple. For a 6–18 month thesis, require evidence that premium adequacy and investment income support returns without relying on unusually favorable catastrophe experience.
• No numeric price target is supportable from the supplied information. The thesis is falsified by sustained deterioration in the underlying combined ratio, material adverse reserve development, or evidence that claims costs are outpacing renewal pricing.